Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flutemetamol (18F) in aMCI conversion to AD
NCT01028053Phase 3Completed
- Sponsor
- GE HealthCare
- Start
- Dec 2009
- Primary completion
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of flutemetamol in Alzheimer's disease (AD), sponsored by GE HealthCare. Started Dec 2009; status: completed.
02
Drugs
flutemetamol
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01028053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01028053.